# Agent 1 - Second-Round Reviewer Response And Manuscript Strategy

Date: 2026-06-14

Scope: reviewer response and manuscript strategy only. This document does not add experiments, alter code, or modify analysis outputs.

## Source Documents Read

- `D:\AKI\AGENT.md`
- second reviewer report
- first-round response format
- revised manuscript
- track-changes manuscript
- supporting information

## Overall Response Strategy

The second-round response should follow the first-round format:

1. Start with a brief thank-you paragraph.
2. For each reviewer point, use `Comment`, `Response`, `Actions taken`, and `Location in the revised manuscript`.
3. Be explicit about what was not possible: no external validation cohort is available in the current revision.
4. Present any new baseline, calibration, or decision-curve analyses only after Agent 2 verifies them.
5. Replace strong clinical-utility language with conditional language: "may support", "has potential", "requires prospective validation", "hypothesis-generating", and "not ready for routine clinical deployment".

The tone should be candid and conservative. The reviewer is mainly asking for methodological restraint, not more novelty language.

## Point-By-Point Draft Strategy

### Major Comment 1 - External Validity And Overfitting

Reviewer concern: single-center retrospective cohort, limited sample size, complex architecture, no external or temporal validation.

Recommended response:

Thank the reviewer and acknowledge that this is the central limitation of the study. State plainly that no external or temporal validation cohort was available for the current revision, so the model should be interpreted as internally validated and exploratory. Explain that the manuscript has been revised to avoid implying external generalizability. If Agent 2 provides additional robustness checks, report them as internal sensitivity analyses, not external validation. State that the revised Discussion now highlights the need for multicenter and temporal validation, model recalibration, and prospective workflow evaluation before clinical deployment.

Actions to take in manuscript:

- Abstract, paragraph P17: remove "significantly improves generalization performance" and "We recommend incorporating..." Replace with internally validated, exploratory wording.
- Introduction, paragraphs P28, P32-P35: soften novelty and "early-warning" claims; remove any statement that implies the model already generalizes beyond the single center.
- Methods/Model Evaluation, paragraph P110: clearly define the evaluation as five-fold internal cross-validation. Avoid calling it external or independent validation.
- Results, paragraph P112: change "independent validation" to "internal cross-validation" or "held-out folds within internal cross-validation".
- Results, paragraphs P116-P117: replace "robust predictive performance" and "reducing underdiagnosis risk in clinical practice" with "promising internal discrimination" and "requires external validation before clinical use".
- Discussion, paragraphs P126, P129-P132: explicitly acknowledge residual overfitting risk despite regularization, augmentation, and cross-validation.
- Supporting information S1-S7: remove deterministic claims that methods "ensure" generalization or "provide robust support" unless verified by analysis.

Do not say:

- "External validation was performed."
- "The model is generalizable."
- "The model is ready for routine clinical implementation."
- "Few-shot learning avoids overfitting."

### Major Comment 2 - Incomplete Clinical Variables

Reviewer concern: model uses preoperative variables only and omits warm ischemia time, pneumoperitoneum pressure, intraoperative hypotension, and blood loss.

Recommended response:

Acknowledge that intraoperative determinants are clinically important and were not available in complete structured form in the retrospective dataset. Clarify that the current model is intentionally a preoperative risk-stratification model, not a full perioperative dynamic prediction model. Add that omission of intraoperative variables likely limits discrimination, calibration, and threshold transportability. Commit to collecting warm ischemia time, pneumoperitoneum pressure/duration, intraoperative hypotension burden, estimated blood loss, operative duration, fluid balance, vasopressor exposure, and nephrotoxic exposure in future prospective or multicenter datasets.

Actions to take in manuscript:

- Abstract, paragraph P17: identify model as "preoperative" and add that intraoperative variables were not included.
- Introduction, paragraph P31: keep the rationale that these factors matter, but avoid implying they are modeled.
- Introduction, paragraph P32: remove "early physiological trends" if the model does not actually include dynamic physiologic trends.
- Methods, paragraphs P72-P77: after clinical feature selection, add a sentence explaining that intraoperative variables were not included because they were unavailable/incomplete in the retrospective dataset.
- Results, paragraph P114 and Discussion, paragraph P130: make this a named limitation, not only a future direction.
- Discussion, paragraph P132: avoid saying the current model supports "real-time risk monitoring"; that would require intraoperative or longitudinal data.

### Major Comment 3 - Model Complexity

Reviewer concern: multimodal fusion, multi-prototype clustering, pseudo-sample generation, and multiple losses may be disproportionate to n=194 and may reduce reproducibility/translation.

Recommended response:

Thank the reviewer and acknowledge the risk that excessive architectural complexity can reduce reproducibility in small cohorts. Explain that the revised manuscript should separate essential model components from exploratory technical details. Keep only the high-level model rationale in the main text; move formulas and implementation details to Supporting information. If Agent 2 can provide ablation or simplified-model comparisons from existing outputs, cite them. If not, do not claim each component is independently necessary.

Actions to take in manuscript:

- Methods, paragraphs P84-P90: shorten claims about the gated fusion design and avoid "improves sensitivity and generalization" unless supported by component-specific analysis.
- Few-Shot Learning Strategy, paragraphs P93-P106: present multi-prototype and loss components as design choices rather than proven independent improvements.
- Training Procedure, paragraph P108: remove "clinical-range validation to ensure reliability and clinical plausibility" unless this is explicitly documented.
- Supporting information S2, S4-S7: reduce promotional language and keep reproducibility details.
- Table 1: consider renaming to a qualitative architecture comparison, not evidence of superiority.

Response nuance:

- It is acceptable to say the design was motivated by class imbalance and small sample size.
- It is not acceptable to say the complexity is justified by clinical translation unless new evidence supports that.

### Major Comment 4 - Baseline Model Comparison

Reviewer concern: clinical-only model performs poorly; optimized classical models are lacking.

Recommended response:

State that additional baseline comparisons have been requested and will be added once verified. Classical models should be evaluated under the same cross-validation structure and preprocessing rules where feasible. Candidate baselines: penalized logistic regression, random forest, gradient boosting, support vector machine, and possibly XGBoost/LightGBM if already available and reproducible. Report the same metrics as the proposed model, especially AUC, balanced accuracy, sensitivity, specificity, precision, F1, MCC, and confidence intervals or fold variability.

Actions to take in manuscript after Agent 2 provides evidence:

- Methods/Model Evaluation, paragraph P110: add a "Baseline comparisons" sentence naming the algorithms and identical resampling framework.
- Results, after paragraph P116: add a concise table comparing proposed model vs classical baselines.
- Discussion, paragraph P126: discuss whether the proposed model improves over baselines modestly or substantially, using measured results only.
- Figures/tables: add or update a comparison table; do not rely only on narrative.

Evidence needed from Agent 2:

- Final baseline table with mean +/- SD or CI across folds.
- Exact preprocessing and tuning procedure for each baseline.
- Confirmation whether baselines use clinical-only variables, imaging features, or both.
- Any statistical comparison if feasible, but avoid overclaiming significance with this sample size.

### Major Comment 5 - Clinical Evaluation: Calibration, DCA, Threshold

Reviewer concern: no calibration metrics or decision-curve analysis; threshold implications insufficiently discussed.

Recommended response:

Agree that discrimination alone is insufficient for clinical evaluation. Add calibration and decision-curve analysis if Agent 2 can generate them reproducibly. Discuss the Youden threshold of 0.332 as an internal threshold only. Explain sensitivity/specificity tradeoffs, false positives, and false negatives in preoperative AKI screening terms. Do not imply a fixed threshold is ready for clinical use.

Actions to take in manuscript after Agent 2 provides evidence:

- Methods/Model Evaluation, paragraph P110: add calibration metrics, calibration curve, Brier score, and DCA methods.
- Results/Model Performance, paragraphs P116-P117: add calibration and net-benefit results; discuss the 0.332 threshold cautiously.
- Discussion, paragraphs P129-P132: state that threshold selection requires local validation and prospective utility testing.
- Figures: add calibration curve and DCA only if generated by Agent 2.

Evidence needed from Agent 2:

- Calibration curve and Brier score.
- Calibration intercept/slope if feasible.
- Decision-curve analysis across clinically relevant threshold probabilities.
- Confusion matrix metrics at threshold 0.332 and any alternative clinically motivated thresholds.

## Minor Comment Strategy

### Length And Condensation

Manuscript remains long and some main-text sections still read like technical documentation. Prioritize condensing:

- Introduction, paragraphs P29-P35.
- Methods, paragraphs P84-P108.
- Supporting information S4-S7 if formulas are broken or text is repetitive.
- Figure legends P193-P203.

### Temper Clinical Utility Claims

Specific phrases needing revision:

- P17: "We recommend incorporating..." -> "These internally validated findings suggest potential value..."
- P34: "enhances clinical utility" -> "provides a descriptive interpretability summary..."
- P35: "early detection and tailored treatment" -> "future validation may clarify whether..."
- P113: "facilitating clinical implementation" -> "supporting exploratory interpretation..."
- P114: "demonstrated significant clinical value" -> "showed promising internal discrimination..."
- P116: "reducing underdiagnosis risk in clinical practice" -> "could be useful if validated externally..."
- P120: "easily incorporated" and "significantly aiding physicians" -> "could potentially be incorporated after workflow validation..."
- P126: "successfully avoids overfitting" and "guarantees" -> "may mitigate overfitting but does not eliminate it..."
- P132: "accurately identifying high-risk patients" -> "identifying patients estimated to be high risk in this cohort..."

### SHAP Interpretation

Recommended response:

Acknowledge that SHAP is descriptive and model-dependent. Revise the manuscript so SHAP is presented as an exploratory explanation of model behavior, not evidence of causality or intervention targets.

Actions:

- Results, paragraphs P119-P124: remove "revealing biological mechanisms", "decisive role", and "clear targets for clinical intervention".
- Discussion, paragraph P126: avoid saying SHAP "guarantees" interpretability.
- Keep SHAP as a rank-order description of feature contributions within the trained model.

### Figures And Legends

Recommended response:

Simplify legends so they state what is shown and avoid interpretation inside figure captions. Add calibration/DCA figures only if Agent 2 generates them. Otherwise, do not promise them.

## Proposed Manuscript Edit Map

| Manuscript area | Current paragraph(s) | Revision purpose |
| --- | --- | --- |
| Abstract | P17 | State single-center retrospective/internal validation; remove recommendation and generalization claims; mention no intraoperative variables. |
| Introduction rationale | P24-P35 | Keep rationale for laparoscopic renal surgery; remove exaggerated novelty/clinical utility; ensure omitted intraoperative variables are framed as rationale and limitation. |
| Clinical features | P72-P77 | Add explicit note that warm ischemia time, pneumoperitoneum pressure, intraoperative hypotension, and blood loss were unavailable/incomplete and not modeled. |
| Data preprocessing/augmentation | P78-P82; SI S1-S2 | Avoid saying augmentation ensures generalization; describe it as a mitigation strategy. |
| Fusion and few-shot methods | P84-P108; SI S4-S7 | Condense; frame complexity as design choices; avoid component-level benefit claims without ablation evidence. |
| Evaluation methods | P110 | Add baselines, calibration, DCA, and threshold analysis only after verified by Agent 2. Clarify internal cross-validation. |
| Results overview | P112-P114 | Replace "independent validation" and clinical implementation language; add baseline/calibration/DCA results only after verified. |
| Model performance | P116-P117 | Discuss threshold 0.332 as internally derived; add false positive/false negative tradeoff; avoid clinical deployment language. |
| SHAP | P119-P124 | Present as descriptive model interpretation; remove causal/interventional wording. |
| Discussion | P126-P132 | Acknowledge overfitting risk, lack of external validation, missing intraoperative variables, no prospective workflow testing; temper clinical translation claims. |
| Figure legends | P193-P203 | Simplify legends and add only verified new figures. |

## Evidence Needed From Agent 2

1. Classical baseline table under comparable internal cross-validation:
   - Penalized logistic regression.
   - Random forest.
   - Gradient boosting.
   - Support vector machine.
   - Any additional model only if reproducible and justified.
2. Clear denominator and sample accounting:
   - Total rows used.
   - Exclusions due to missing outcome, missing image, or missing annotation.
   - Outcome distribution in the final analytic set.
3. Calibration:
   - Brier score.
   - Calibration curve.
   - Calibration slope/intercept if feasible.
4. Decision-curve analysis:
   - Net benefit across clinically relevant threshold range.
   - Figure/table suitable for manuscript or supplement.
5. Threshold analysis:
   - Metrics at Youden threshold 0.332.
   - Sensitivity/specificity tradeoff and false-positive/false-negative counts.
6. Any available ablation/simplification evidence:
   - With vs without imaging.
   - Single-prototype vs multi-prototype if already reproducible.
   - Without pseudo-sample/anchor/triplet components only if feasible without inventing new outputs.

## Suggested Opening Response Letter Paragraph

Dear Dr. Irfan Ullah and Reviewer,

We sincerely thank you for the careful second-round review and for highlighting issues central to the interpretation of this work, particularly external validity, model complexity, incomplete intraoperative variables, baseline comparisons, calibration, and decision-curve evaluation. In this revision, we have aimed to make the manuscript more conservative and transparent. We explicitly acknowledge that the present study is a single-center retrospective analysis with internal cross-validation only, and that external, temporal, and prospective validation are required before clinical deployment. We have also revised claims about clinical utility and SHAP interpretation, clarified the absence of key intraoperative variables, and added additional analyses where reproducibly available.

## Bottom Line For The Revision

The safest strategy is to present the study as an exploratory, internally validated, single-center proof-of-concept for multimodal preoperative AKI risk prediction. The response should not defend the current model as clinically ready. It should show the reviewer that the authors understand the limits, have added fair comparisons and clinical evaluation where possible, and have restrained the manuscript's claims accordingly.
